Conversations That Matter forum examines importance of burgeoning industry to B.C. economy
Article content
A biotechnology forum hosted by Stuart McNish and Conversations that Matter on Tuesday heard 16,000 additional workers are needed for Metro Vancouver’s biotech industry by 2030.
Advertisement 2
Article content
The forum comprised Suzanne Gill, president and CEO of Genome B.C.; Andrew Booth, chief financial officer at AbCellera (a Vancouver biotechnology company that helped produce the first antibody drug approved to treat COVID-19); Allen Eaves, president and CEO of Stemcell Technologies; Brenda Bailey, B.C. minister of jobs, economic development and innovation; Darryl Knight, president of Providence Research and Wendy Hurlburt, president and CEO of Life Sciences B.C.
Article content
Bailey said the government had recently released its Life Sciences and Biomanufacturing Strategy that found the local biotech industry and its 18,0000 workers were “punching above” their weight. Based on growth projections, it’s estimated the sector needs another 16,000 workers over the next six years.
Article content
Advertisement 3
Article content
She said the provincial and federal governments had funded a national biotech training centre and that government wanted to do more to attract biotech workers and to retain locally-grown scientists.
Eaves suggested opening another school of medicine in B.C. to attract researchers, with those workers ultimately fuelling research crucial to the local biotech centre.
The forum compared B.C. to Ireland, which has been working on its biotech since the 1970s and is now a major international drug maker. Ireland has far fewer companies than B.C.’s 1,200, but employs more workers and has a much larger economic footprint.
Gill said the local industry needed to create a cohesive vision and have all sectors — companies, investors and government — on board.
Advertisement 4
Article content
Booth said he had visited biotech companies in San Francisco and Boston where half the employees were Canadian.
“We need great companies here to give them meaningful jobs,” he said.
Knight said there were hundreds of clinical trials conducted in B.C. every month, but they were mostly stage two and three trials. Bailey said the government was working on attracting more stage one trials.
Hurlburt said a focus was needed to retain and return Canadians scientists to the province.
dcarrigg@postmedia.com
-
B.C. biotech company AbCellera Biologics goes public, shares surge 170% on Nasdaq
-
Better treatment, potential cures for diseases as stem cell robotics debut at B.C. Children’s Hospital
-
B.C.’s ‘world-class’ biotech sector plays key role in developing COVID-19 treatments and vaccines
Spring subscription sale: Our in-depth journalism is possible thanks to the support of our subscribers. For a limited time, you can get full online access to the Vancouver Sun and The Province, along with the National Post and 13 other Canadian news sites, for just $40 for one year or $1 a week for 52 weeks. Support our journalism by subscribing today: The Vancouver Sun | The Province.
Comments
Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.
Join the Conversation